COMP-Angiopoietin-1 decreases lipopolysaccharide-induced acute kidney injury  by Kim, Duk Hoon et al.
COMP-Angiopoietin-1 decreases lipopolysaccharide-
induced acute kidney injury
Duk Hoon Kim1, Yu Jin Jung1, Ae Sin Lee1, Sik Lee1, Kyung Pyo Kang1, Tae Hwan Lee1, Sang Yong Lee2,
Kyu Yun Jang3, Woo Sung Moon3, Kyu-Sil Choi4, Kwon-Ha Yoon5, Mi Jeong Sung6, Sung Kwang Park1
and Won Kim1
1Renal Regeneration Laboratory and Department of Internal Medicine, Research Institute of Clinical Medicine, Chonbuk National
University Medical School, Jeonju, Korea; 2Department of Diagnostic Radiology, Research Institute of Clinical Medicine, Chonbuk
National University Medical School, Jeonju, Korea; 3Department of Pathology, Research Institute of Clinical Medicine, Chonbuk National
University Medical School, Jeonju, Korea; 4Molecular and Cellular Imaging Center, Samsung Biomedical Research Institute, Seoul, South
Korea; 5Institute for Radiological Imaging Science, Wonkwang University School of Medicine, Iksan, South Korea and 6Food Function
Research Division, Korea Food Research Institute, Song nam, South Korea
During sepsis endothelial dysfunction is an important
pathogenetic mechanism in acute kidney injury (AKI).
Lipopolysaccharide (LPS)-induced endotoxemia is associated
with renal hemodynamic changes such as alterations of renal
blood flow (RBF), vascular resistance, and glomerular
filtration rate. We used adenoviral delivery of an engineered
variant of native angiopoietin-1 (COMP-angiopoietin-1)
containing anti-inflammatory and anti-permeability
functions, to determine if regulation of renal endothelial cell
dysfunction may have a beneficial role in preventing AKI
during LPS-induced endotoxemia in mice. This treatment
prevented the endotoxin-induced decrease of RBF and mean
arterial pressure while improving glomerular filtration rate.
Treatment also mitigated the effects of LPS on renal
intercellular adhesion molecule-1 and vascular cell adhesion
molecule-1 protein expression, the number of ER-HR3-
positive macrophages that infiltrated the kidney, serum
nitrate/nitrite levels, renal inducible nitric oxide synthase
protein expression, the induction of tubular epithelial
reactive oxygen and nitrogen species, and renal
microvascular permeability. Our findings show that
COMP-angiopoietin-1, an endothelium-oriented therapeutic
agent, protects against AKI caused by endotoxemia.
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Sepsis is a systemic inflammatory response to infection and is
associated with the production of nitric oxide (NO), platelet
activation factor, and eicosanoids. Sepsis has been implicated
in endothelial cell dysfunction, increased permeability,
hypotension, inadequate organ perfusion, and cell death
associated with multiple organ failure.1 Acute kidney injury
(AKI) occurs in about half of the patients in septic shock, and
mortality from septic AKI is extremely high.2
Endotoxins produced by bacteria, such as lipopolysacchar-
ide (LPS), are associated with renal hemodynamic changes such
as alteration of renal blood flow (RBF), renal vascular
resistance, and glomerular filtration rate.3,4 Renal microvascular
injury is a major mechanism of AKI, and peritubular capillary
dysfunction in endotoxemia contributes to LPS-induced renal
injury.3,5–8 Thus, peritubular endothelial dysfunction is an
important pathogenetic mechanism in AKI in sepsis.
Another hallmark of vascular dysfunction in sepsis is
hyperpermeability secondary to microcirculatory/capillary
leakage.9 The presence of profound vascular leakage with the
movement of fluid and macromolecules into the renal
interstitium is an essential feature of AKI in sepsis, and
changes in vascular endothelial integrity with increased
permeability contribute to the development of renal failure.
Therefore, an endothelial-specific modality to normalize
renal hemodynamics, inflammation, and renal vascular
permeability may decrease AKI in sepsis and subsequently
improve the mortality rate in septic patients.
Angiopoietin-1 (Ang1) is an angiogenic factor essential to
embryonic vascular development through its actions on an
endothelial receptor tyrosine kinase.10,11 Ang1 also decreases
vascular permeability12 and has anti-inflammatory13 and
anti-apoptotic14 properties. Ang1 improves hemodynamic
function, reduces lung injury, lowers expression of inflam-
matory adhesion molecules, and preserves endothelial nitric
oxide synthase (eNOS) activity in the lung tissue in an LPS-
induced endotoxic shock model.15,16 COMP-Ang1, a variant
of native Ang1 engineered by replacing the N-terminus of
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Ang1 with cartilage oligomeric matrix protein (COMP), is
more potent than native Ang1 in phosphorylating Tie2 and
signaling through Akt in primary cultured endothelial cells.17
Recently, we have demonstrated that treatment with COMP-
Ang1 decreases the progression of renal fibrosis in a unilateral
ureteral obstruction model. Thus, COMP-Ang1 may have
potential as an endothelium-oriented therapeutic agent in
chronic renal disease.18 However, there have been no reports
about the possible effects of COMP-Ang1 on septic AKI.
In this study, we examined whether COMP-Ang1 has
renoprotective effects using a murine model of AKI. Our
results demonstrated that COMP-Ang1 treatment improves
renal function by regulating renal hemodynamics, preserving
renal endothelial cells integrity, decreasing expression of
intercellular adhesion molecule-1 (ICAM-1) and vascular cell
adhesion molecule-1 (VCAM-1) and macrophage infiltra-
tion, ameliorating serum NO levels and inducible nitric oxide
synthase (iNOS) expression, suppressing renal reactive
oxygen species (ROS) and reactive nitrogen species (RNS),
and decreasing LPS-induced increased renal vascular perme-
ability in a mouse model of LPS-induced endotoxemic AKI.
RESULTS
Effect of COMP-Ang1 on renal hemodynamics and renal
function during endotoxemia
Treatment of mice with LPS significantly decreased mean
arterial pressure (MAP) compared with vehicle alone.
Pretreatment with COMP-Ang1 adenovirus attenuated the
LPS-induced decrease of MAP (Figure 1a). RBF was
significantly lower in mice treated with LPS than that in
mice treated with vehicle, but COMP-Ang1 prevented much
of the LPS-induced lowering of RBF (Figure 1b). The
calculated renal vascular resistance (MAP/RBF) was signifi-
cantly lower in the group treated with COMP-Ang1 and LPS
than in the group treated with LPS only (Figure 1c).
Treatment with COMP-Ang1 alone did not alter MAP, RBF,
or renal vascular resistance, producing similar results to
treatment with vehicle alone (Figure 1a–c). Our data showed
that serum creatinine tended to increase after treatment with
LPS than after treatment with control buffer. However, this
did not reach statistical significance (0.35±0.07mg/dl in
control buffer-treated mice, 0.53±0.12mg/dl in LPS-treated
mice, n¼ 4 in each group). Blood urea nitrogen levels after
treatment with LPS were significantly higher than after
treatment with control buffer (22.5±9.1mg/dl in control
buffer-treated mice, 81.4±24.7mg/dl in LPS-treated mice,
n¼ 4 in each group, Po0.05). Treatment with COMP-Ang1
did not significantly decrease the LPS-induced increase of
blood urea nitrogen (81.4±24.7mg/dl in LPS-treated mice,
80.0±17.6mg/dl in LPS plus COMP-Ang1-treated mice,
n¼ 4 in each group). As chromagens in mouse serum may
affect the serum creatinine levels when the picric acid method
is used for measurement and as inulin clearance has been
considered as the gold-standard method for measuring
glomerular filtration rate, we also measured glomerular
filtration rate by inulin clearance. The inulin clearance of
mice treated with LPS was significantly lower than that in
mice treated with vehicle or COMP-Ang1 alone. COMP-
Ang1 significantly attenuated the LPS-induced decrease in
the inulin clearance (Figure 1d). The inulin clearance of the
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Figure 1 | Effects of COMP-Ang1 on mean arterial pressure, renal blood flow, renal vascular resistance, and glomerular filtration
rate during endotoxemia in mice. COMP-Ang1 or vehicle was injected 3 days before lipopolysaccharide (LPS, 8mg/kg, i.p.) or control
buffer injection (n¼ 8 in each group). Sixteen hours after LPS or control buffer injection, mean arterial pressure was measured through the
carotid artery (a), renal blood flow was measured using a blood flowmeter (b), and renal vascular resistance was calculated as mean arterial
pressure/renal blood flow (c). Glomerular filtration rate was measured by inulin clearance (d) (n¼ 10 in each group). COMP-Ang1, COMP-
angiopoietin-1; i.p., intraperitoneally; LPS, lipopolysaccharide. **Po0.01 versus control bufferþ vehicle; wPo0.05 versus LPSþ vehicle.
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mice treated with COMP-Ang1 alone did not differ from
that of mice treated with vehicle alone. These data suggest
that COMP-Ang1 improves renal hemodynamics and the
glomerular filtration rate in endotoxemic mice.
COMP-Ang1 ameliorates LPS-induced renal endothelial injury
PECAM-1 and vWF are markers of endothelial cell and Ang1
is an antiapoptotic factor in endothelial cells.18–20 We
evaluated whether pretreatment with COMP-Ang1 preserves
renal PECAM-1-positive peritubular capillary endothelial
cells in mice with LPS-induced endotoxemia. COMP-Ang1
reduced the LPS-induced decrease of PECAM-1-positive
endothelial cells (Figure 2a–d). Immunohistochemical ana-
lyses of kidneys showed that also induction of endotoxemia
with LPS significantly decreased the area densities of vWF-
positive cells compared with those of vehicle or COMP-Ang1
alone. The addition of COMP-Ang1 to the LPS treatment
prevented much of the decrease in the density of vWF
immunoreactivity that was induced by treatment with LPS
only (Figure 2e). To evaluate the antiapoptotic effect of
COMP-Ang1 in LPS-treated renal endothelial cells, we
stained kidney sections for PECAM-1 and TUNEL. The
number of cells in the kidney positive for both PECAM-1 and
TUNEL was higher after 12 h treatment with LPS than after
treatment with control buffer. COMP-Ang1 decreased the
LPS-induced increase in the number of PECAM-1- and
TUNEL-positive cells in the kidney (Figure 2f–j).
Electron microscopy of peritubular endothelial cells in
mice treated with vehicle alone showed normal cellular
architecture. In contrast, an ultrastructural analysis of
peritubular endothelial cells in LPS-treated mice showed
severe subcellular injuries. Endothelial cells were detached
from the basement membrane, and the plasma membrane
was destroyed. Treatment with COMP-Ang1 prevented the
LPS-induced destruction of the endothelial cell integrity.
The junction of the endothelial cells and basement mem-
brane was well preserved, and the plasma membrane and the
intracellular organelles were also relatively well preserved
(Figure 2k–m). These results indicate that COMP-Ang1
preserves the integrity of renal endothelial cells in endotoxe-
mic mice.
COMP-Ang1 decreases LPS-induced renal ICAM-1 and
VCAM-1 protein expression
Lipopolysaccharide induces vascular inflammation and
compromises vascular function; renal interstitial ICAM-1
and VCAM-1 protein expression may therefore be associated
with LPS-induced renal injury.21 Immunoblot analyses were
used to evaluate the changes in ICAM-1 and VCAM-1
expression in the kidneys. The expression of ICAM-1 was
about sevenfold higher in kidneys from LPS-treated mice
than in kidneys from the control mice treated with vehicle
alone. The administration of COMP-Ang1 adenovirus
inhibited the LPS-induced increase in ICAM-1 protein
expression by about 65% (Figure 3a). LPS significantly
increased renal VCAM-1 protein expression to about 3.2-fold
the expression level after vehicle treatment. The increase in
the renal VCAM-1 protein level after treatment with COMP-
Ang1 and LPS was about 53% of the increase after LPS alone
(Figure 3b). However, COMP-Ang1 alone did not change
renal ICAM-1 or VCAM-1 protein expression.
COMP-Ang1 suppresses LPS-induced ICAM-1 expression
and ER-HR3-positive macrophage infiltration in the renal
interstitial space
We performed immunohistochemical studies to localize ICAM-
1 expression and to evaluate changes in the number of ER-HR3-
positive macrophages in endotoxemic mice. ICAM-1 was
upregulated throughout the renal interstitial space after LPS
treatment (Figure 3e and g). Pretreatment with COMP-Ang1
adenovirus significantly decreased the LPS-induced expression
of interstitial ICAM-1 (Figure 3f and g). LPS treatment
increased the infiltration of ER-HR3-positive macrophages into
the kidney by sevenfold over than that in the kidney from
mice treated with vehicle alone (Figure 4). Pretreatment with
COMP-Ang1 decreased the LPS-induced accumulation of
ER-HR3-positive macrophages in kidney by about 60%,
whereas COMP-Ang1 alone had no effect (Figure 4).
COMP-Ang1 protein treatment after LPS injection also
suppresses LPS-induced ICAM-1 expression and
ER-HR3-positive macrophage infiltration in the kidney
We administered COMP-Ang1 protein (200 mg) just after LPS
injection and evaluated the changes of ICAM-1 expression
and the number of ERHR-3-positive macrophages in
kidney after 16 h. Treatment with COMP-Ang1 protein after
LPS injection also significantly decreased the LPS-induced
ICAM-1 protein expression and the number of LPS-induced
ERHR-3-positive macrophages in kidney (Supplementary
Figure 1).
COMP-Ang1 decreases serum nitrate/nitrite levels and
renal iNOS protein expression in LPS-induced AKI
As renal hemodynamic changes are strongly influenced by the
production of NO in endotoxemic mice, and serum nitrate
and nitrite are markers of NO generation in vivo.22 we
evaluated the effect of COMP-Ang1 adenovirus on serum
levels of nitrate and nitrite in LPS-induced AKI. LPS induced
about a 14-fold rise in serum nitrate and nitrite levels
compared with the levels in the serum from the control mice
treated with vehicle alone. Nitrate and nitrite levels in mice
treated with LPS and COMP-Ang1 were 33% lower than in
mice treated with LPS alone (Figure 5a). COMP-Ang1 alone
did not alter the levels of serum nitrate and nitrite showing
that COMP-Ang1 itself did not affect NO generation.
Induction of iNOS protein expression in the kidney is
accompanied by a significant increase in serum NO
levels.23,24 To ascertain the above findings, we also investi-
gated the effect of COMP-Ang1 on renal iNOS protein
expression in LPS-induced AKI. Administration of LPS
resulted in an approximately 13-fold increase in renal iNOS
protein expression over the expression in mice treated with
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Figure 2 |Effects of COMP-Ang1 on renal endothelial cell injury during endotoxemia in mice. (a–d) Immunofluorescence stain of PECAM-1
in the kidney. Kidneys from mice treated with control buffer plus vehicle (a), control buffer plus COMP-Ang1 (b), lipopolysaccharide
(LPS) plus vehicle (c), and LPS plus COMP-Ang1 (d) were harvested 16 h after LPS or control buffer treatment. Scale bar¼ 50 mm and applies
to panels a–d. (e) Quantitative score of vWF in kidney. Bar graph shows the area density of the positively stained area to the total field
(0.22mm2). Data are expressed as mean±s.d., n¼ 4 in each group. (f–i) Immunofluorescence double-staining of PECAM-1 and TUNEL in
kidney. Scale bar¼ 20mm and applies to panels f–i. (j) The number of PECAM-1- and TUNEL-positive cells per kidney section (mean area
of kidney section; 17.81±2.37mm2). **Po0.01 versus control bufferþ vehicle; wPo0.05 versus LPSþ vehicle. (k–m) Electron micrographs
of peritubular endothelial and tubular epithelial cells in mice treated with control buffer plus vehicle (k), LPS (8mg/kg, i.p.) plus vehicle (l),
and LPS plus COMP-Ang1 (m). Photographs show representative examples from three experiments per treatment group. Arrows indicate
peritubular endothelial cells. T, tubular epithelial cells; RBC, red blood cell. Scale bar¼ 1 mm and applies to panels k–m.
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vehicle or COMP-Ang1 alone. Pretreatment with COMP-
Ang1 suppressed the LPS-induced increase in iNOS expres-
sion by about 80% (Figure 5b). Thus, COMP-Ang1
attenuated the induction of iNOS expression as well as
serum NO levels in LPS-induced AKI.
COMP-Ang1 decreases renal vascular permeability and
increases renal tissue blood flow
As endotoxin-induced AKI is associated with increased
microvascular leakage in the kidney, we examined the effect
of COMP-Ang1 adenovirus on the kidney vasculature in
LPS-induced AKI by measuring the leakage of Evans blue
dye.25 Treatment with LPS increased renal vascular perme-
ability compared with treatment with vehicle or COMP-Ang1
alone. Pretreatment with COMP-Ang1 significantly prevented
the LPS-induced increase in renal vascular permeability
(Figure 6a). The renal vascular permeability was similar in
mice treated with vehicle alone and COMP-Ang1 alone.
In addition, influence of COMP-Ang1 adenovirus on renal
cortical and medullary blood flow was also measured by a
laser-Doppler flow ultrasonography. Treatment with LPS
decreased renal cortical and medullary blood flow by about
73.2 and 76.0%, respectively, compared with vehicle alone.
After LPS with COMP-Ang1 treatment, renal cortical and
medullary blood flow were about 2.7-fold and 2.3-fold
higher, respectively, than after LPS treatment alone (Figure 6b).
However, COMP-Ang1 alone had no effect on the cortical or
medullary blood flow.
COMP-Ang1 suppresses renal tubular ROS/RNS production in
endotoxemic mice
Dihydrorhodamine-123 (DHR) is oxidized to fluorescent
rhodamine by hydroxyl radicals, nitrogen dioxide, peroxynitrite,
and peroxidase-derived species, which are ROS or RNS.26
Thus, the oxidation of DHR to rhodamine can be used as an
indicator of ROS/RNS generation. Wu et al.3,27 demonstrated
that renal peritubular capillary dysfunction with reduced
perfusion increases rhodamine fluorescence in renal tubular
epithelial cells and induces AKI in the cecal-ligation-
and-puncture murine model of sepsis. We demonstrated
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Figure 3 | Effects of COMP-Ang1 on the protein expressions of ICAM-1 and VCAM-1 in endotoxemic mice. (a and b) Immunoblot
analyses of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in kidney. COMP-Ang1 or vehicle
was injected 3 days before lipopolysaccharide (LPS) (8mg/kg, i.p.) or control buffer injection. Kidneys were harvested 16 h after LPS or
control buffer injection. Results from from independent experiments were similar. Densitometric analyses are presented as the relative ratio
of ICAM-1 or VCAM-1 to actin. The relative ratio measured in the control buffer plus vehicle group is arbitrarily presented as 1. Data are
expressed as mean±s.d. (c–g) Immunohistochemical study of ICAM-1 in kidney. Kidneys from mice treated with control buffer plus vehicle
(c), control buffer plus COMP-Ang1 (d), LPS plus vehicle (e), and LPS plus COMP-Ang1 (f) were harvested 16 h after LPS or control buffer
treatment. Scale bar¼ 50mm. (g) Quantitative score of ICAM-1 in kidney (n¼ 4 in each group). Bar graph shows the area density of the
positively stained area to the total field (0.22 mm2). Data are expressed as mean±s.d. **Po0.01 versus control bufferþ vehicle; wPo0.05
versus LPSþ vehicle.
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that COMP-Ang1 adenovirus improved renal cortical and
medullary blood flow in mice with LPS-induced endo-
toxemia (Figure 6b). Therefore, we used DHR with laser
scanning confocal microscopy and intravital microscopy to
evaluate whether COMP-Ang1 treatment can decrease renal
epithelial ROS/RNS generation in LPS-induced kidney injury.
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Figure 4 | Immunofluorescence study of ER-HR3-positive macrophages in kidney. Kidneys from mice treated with control buffer plus
vehicle (a–c), control buffer plus COMP-Ang1 (d–f), lipopolysaccharide (LPS) (5mg/kg, i.p.) plus vehicle (g–i), and LPS plus COMP-Ang1 (j–l)
were harvested 5 days after LPS or control buffer treatment. Tissues were fixed in 4% formaldehyde solution and frozen sections were then
stained with ER-HR3 antibody (a, d, g, and j) and DAPI (b, e, h, and k). Scale bar¼ 50 mm. Quantitative score of ER-HR3-positive
macrophages (m) in kidney, n¼ 5 for each experimental group. Bar graph shows the number of the unit area. Data are expressed as
mean±s.d. **Po0.01 versus control bufferþ vehicle; wPo0.05 versus LPSþ vehicle.
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Confocal microscopic images showed an increased
rhodamine fluorescence in the renal epithelial cells of mice
treated with LPS compared with that in the renal epithelial
cells from mice treated with vehicle or COMP-Ang1 alone.
Pretreatment with COMP-Ang1 decreased the LPS-induced
intensity of rhodamine fluorescence in the renal tubular
epithelial cells (Figure 7).
Representative intravital microscopic images of rhoda-
mine fluorescence from the kidney of mice after LPS
treatment are shown in Figure 8 and Supplementary video
clips. The intensity of rhodamine fluorescence was markedly
increased in tubular epithelial cells by the LPS treatment
(Figure 8c and Supplementary Video Clips 1 and 3). Pretreat-
ment with COMP-Ang1 reduced the increase in LPS-induced
rhodamine fluorescence (Figure 8d and Supplementary
Video clip 4). COMP-Ang1 alone had no significant effect
on ROS/RNS generation (Figure 8b and Supplementary
Video clip 2). These results suggest that COMP-Ang1
decreases LPS-induced ROS/RNS production in the renal
tubular cells of endotoxemic mice.
COMP-Ang1 increases renal Akt phosphorylation through
Tie2 in endotoxemic mice
Phosphorylation of Akt in endothelial cells is an important
downstream pathway of COMP-Ang1.19 COMP-Ang1 in-
creased renal Akt phosphorylation 16 h after LPS injection
compared with the levels in mice treated with control buffer.
The mean increases in Akt phosphorylation after treatment
with COMP-Ang1 were 2.2-fold at 16 h (Figure 9). Injection
of LPS itself did not significantly activate phosphorylation of
Akt in kidney. Treatment with COMP-Ang1 itself increased
phosphorylation of Akt in kidney. To determine the involve-
ment of Tie2 in COMP-Ang1-induced Akt phosphory-
lation in LPS-treated kidney, mice were pretreated with
sTie2-Fc 24 h before the COMP-Ang1 treatment. Pretreat-
ment with sTie2-Fc prevented the COMP-Ang1-induced Akt
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Figure 6 |Renal vascular permeability and renal tissue blood flow in the kidneys of lipopolysaccharide (LPS)-induced endotoxemic
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phosphorylation, indicating that COMP-Ang1-induced Akt
phosphorylation occurs primarily through Tie2 in the kidney
(Figure 9).
DISCUSSION
Clinical and experimental studies have indicated that changes
in renal hemodynamics may have a critical role in AKI.28–30
LPS induces renal hemodynamic changes including RBF and
glomerular filtration rate. Decreased peritubular capillary
perfusion has also been associated with renal injury in a
murine model of LPS-induced endotoxemia.3 Thus, pre-
servation of renal hemodynamics with maintenance of
peritubular capillary perfusion may protect against AKI in
models of sepsis.
Recent studies have suggested that Ang1 exhibits protec-
tive effects against endotoxemia, increasing vasoconstric-
tion31 and reducing pulmonary microvascular leakage
associated with inflammation.15 It has been reported that
circulating Ang1 levels were suppressed in critically ill
patients with septic shock.32 Schabbauer et al.33 have
demonstrated that inhibition of the phosphoinositide 3-kinase-
Akt pathway enhanced LPS-induced endothelial E-selectin
expression and they have also suggested that this pathway
suppresses LPS-induced inflammation in endotoxemic mice.
Thus, Ang1, which phosphorylates the phosphoinositide
3-kinase-Akt pathway in endothelial cell, has the potential to
increase vascular reactivity and decrease inflammation in
endotoxemia.
In our experiment, treatment with LPS tended to increase
serum creatinine more than treatment with control buffer,
but this difference did not reach statistical significance.
Interference by serum chromagens of the serum creatinine
measurement and the high standard deviation might have
contributed to this lack of statistical significance. Blood urea
nitrogen levels were significantly higher after treatment with
LPS than after treatment with control buffer; however,
COMP-Ang1 did not significantly decrease blood urea
nitrogen from the levels seen after treatment with LPS. As
chromagens in mouse serum may affect the serum creatinine
levels when the picric acid method is used for measurement
Control buffer
+ vehicle
Control buffer
+ COMP-Ang1
LPS + vehicle
LPS +
COMP-Ang1
Figure 7 |Confocal laser scanning microscopy of rhodamine in the kidneys of lipopolysaccharide (LPS)-induced endotoxemic mice.
The oxidation of dihydrorhodamine-123 (DHR) to rhodamine was used as an indicator of reactive oxygen species/reactive nitrogen species
generation in kidney. COMP-Ang1 or vehicle was administered 3 days before the injection of LPS (8mg/kg, i.p.) or control buffer. DHR
(3mg/kg) was administered i.v. 16 h after the injection of LPS. Kidneys from mice treated with control buffer plus vehicle (a–c), control buffer
plus COMP-Ang1 (d–f), LPS plus vehicle (g–i), and LPS plus COMP-Ang1 (j–l) were harvested 15min after the DHR injection. Note that the
intensity of rhodamine was increased in renal tubular epithelial cells (g; arrow and inset), and this increased intensity was lower in the LPS
plus COMP-Ang1 group than in the LPS plus vehicle group, n¼ 3 for each experimental group. Scale bar¼ 50mm.
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and as inulin clearance has been considered as the gold-
standard method for measuring the glomerular filtration rate,
we also measured the inulin clearance.
Interactions between leukocytes and adhesion molecules
on endothelial cells can be an important mechanism of LPS-
induced inflammation. The increased expression of ICAM-1
represents an early inflammatory response to LPS and
suggests that endothelial inflammation may propagate
inflammatory cell infiltration, leading ultimately to renal
injury. Macrophages have been implicated in the pathogen-
esis of AKI.34 Therefore, downregulation of ICAM-1 expres-
sion decreases the infiltration of inflammatory cells into the
kidney. Thus, in this experiment we evaluated ICAM-1
expression in kidney 12 h after LPS injection and changes in
the number of ERHR-3-positive macrophages in kidney 5
days after LPS injection. Our data demonstrated that
treatment with COMP-Ang1 decreased LPS-induced ICAM-
1 expression and ERHR-3-positive macrophage infiltration in
the kidney.
However, the role of COMP-Ang1, a variant of Ang1,
in AKI has not been examined. Our results revealed
that COMP-Ang1 attenuates LPS-induced renal dysfunction
by regulating renal hemodynamics, preserving renal endo-
thelial cells, and decreasing ICAM-1 and VCAM-1 protein
expression and macrophage infiltration in a model of
endotoxemic AKI.
Recently, Long et al.35 have reported that Ang1 has
profibrotic and inflammatory effects in folic acid-induced
acute renal injury. However, our data demonstrated that
COMP-Ang1 suppressed ICAM-1 and VCAM-1 protein
expression and macrophage infiltration in LPS-induced
endotoxemic AKI. It has been found that dose and the form
of Ang1 may have an important role in outcome.35 Thus,
these findings suggest that the anti-inflammatory effect of
Ang1 may be different according to the kidney disease model.
Renal hemodynamic is dramatically changed after LPS
injection. LPS-induced renal hemodynamic changes are
associated with dysfunction of the renal vasculature. Thus,
measurement of renal hemodynamic parameters, such as
renal arterial blood flow and blood flow in cortex and
medulla, are important in LPS-induced AKI. Data about RBF
reflect the renal hemodynamics associated with systemic
circulation and data about blood flow in the cortex and
medulla reflect the renal hemodynamics in the microcircula-
tion. In this experiment, our data demonstrated that COMP-
Ang1 ameliorated the LPS-induced decrease of RBF in the
renal artery and in cortex and medulla of the renal tissue.
Wu et al.27 have demonstrated that decreased peritubular
capillary perfusion increases ROS/RNS production in epithe-
lial cells and subsequently increases tubular cell injury. They
Control buffer + COMP-Ang1Control buffer + vehicle
LPS + vehicle LPS + COMP-Ang1
Figure 8 | Intravital microscopic images of rhodamine
fluorescence from the kidney from lipopolysaccharide
(LPS)-induced endotoxemic mice. The oxidation of
dihydrorhodamine-123 (DHR) to rhodamine was used as an
indicator of reactive oxygen species/reactive nitrogen species
generation in kidney. LPS, COMP-Ang1, and DHR were
administered as described in Figure 7 legend. Kidneys from mice
treated with control buffer plus vehicle (a), control buffer plus
COMP-Ang1 (b), LPS plus vehicle (c), and LPS plus COMP-Ang1 (d)
were observed 15min after the DHR injection. Note that the
expression of rhodamine in renal tubular epithelial cells from mice
treated with LPS plus vehicle was lower in kidneys from mice
treated with LPS plus COMP-Ang1, n¼ 3 for each experimental
group. Scale bar¼ 50mm.
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Figure 9 | Immunoblot analyses of Akt and phospho-Akt from
the kidneys of lipopolysaccharide (LPS)-induced endotoxemic
mice. Kidneys were harvested 16 h after LPS or control buffer
injection. Mice were pretreated with 1 108 PFU Ade-sTie2-Fc
24 h before treatment with 1 108 PFU Ade-COMP-Ang1.
COMP-Ang1 adenovirus was administered 3 days before LPS
injection. Each lane contains 150mg total protein. Blots were
probed with an anti-phospho-Akt (p-Akt) antibody. The
membrane was stripped and reprobed with an anti-Akt antibody
to control for protein loading in each lane. Results were similar
from six independent experiments. Densitometric analyses are
presented as the relative ratio of p-Akt to Akt. The relative ratio
measured in kidneys treated with control buffer plus vehicle is
arbitrarily presented as 1. Results from three independent
experiments were similar. Data are expressed as mean±s.d.
*Po0.05 versus control bufferþ vehicle; #Po0.05 versus control
bufferþ vehicle.
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suggest that ROS/RNS in epithelial cells should be considered
as potential therapeutic targets for the treatment of sepsis-
induced AKI. We demonstrated that COMP-Ang1 amelio-
rates LPS-induced endothelial dysfunction and attenuates the
LPS-induced decrease of renal cortical and medullary blood
flow (Figure 6). Our data also demonstrated that treatment
with COMP-Ang1 decreases the LPS-induced production of
ROS/RNS in renal tubular epithelial cells. Therefore, as
COMP-Ang1 acts on the renal endothelial Tie2 receptor, our
data suggest that COMP-Ang1 suppresses LPS-induced RNS/
ROS production in renal tubular epithelial cells through
actions on renal endothelial cells.
A major limitation of this experiment is that pretreatment
is necessary because adenovirus is used as a delivery vehicle.
Systemic administration of conventional adenovirus can lead
to the accumulation of virus particles in the liver, which may
cause liver injury. Therefore, the systemic administration of
COMP-Ang1 using adenovirus may have limited clinical
applicability. For this reason, a novel adenovirus with
minimal hepatic dysfunction or lipid formulations such as
liposomes and micellar solutions will be needed for the
development of clinical applications of COMP-Ang1, as it
will take about 3 days to reach the peak concentration of
COMP-Ang1.
The alterations in glomerular filtration rate and RBF in
our experiment could cause problems in probe delivery and
clearance from the kidneys, especially in the immunofluor-
escence staining and inulin-fluorescein isothiocyanate (FITC)
experiments. We used a control antibody in the immuno-
fluorescence staining experiment and found that there was no
significant signal from kidney section.
COMP-Ang1 protects against LPS-induced AKI by
significantly improving renal hemodynamics, iNOS-induced
NO production, ICAM-1 and VCAM-1 protein expression,
renal tissue blood flow, and epithelial ROS/RNS production
in endotoxemic mice. COMP-Ang1 may therefore be a novel,
endothelium-targeted therapy for preventing LPS-induced
AKI in sepsis.
MATERIALS AND METHODS
Animal experiments
C57BL/6 mice (Charles River Korea, Seoul, Korea; 20–30 g body
weight) were used in these experiments. All animal studies were
reviewed and approved by the Institutional Animal Care and Use
Committee of Chonbuk National University. Recombinant adeno-
viruses expressing COMP-Ang1 or LacZ were constructed using
previously published methods.17 For adenoviral treatment, Ade-
COMP-Ang1 or Ade-LacZ (vehicle) diluted in 50 ml of sterile 0.9%
NaCl was injected intravenously (i.v.) through the tail vein. In our
previous experiments, circulating serum levels of COMP-Ang1
increased 3 days after treatment, peaked at 5 days, and declined
thereafter.18 To evaluate the effect of high levels of COMP-Ang1 in
the endotoxemic model, mice received an i.v. injection of COMP-
Ang1 adenovirus or vehicle adenovirus 3 days before LPS injection.
At 16 h after the injection of LPS (8mg/kg) or control buffer,
mice were anesthetized with ketamine (100mg/kg) and xylazine
(10mg/kg), and subsequently killed by cervical dislocation. Kidneys
were harvested for immunoblotting and immunohistochemistry. To
determine the effects of COMP-Ang1 on ER-HR3-positive macro-
phage cell infiltration in kidneys, the kidneys were used for ER-HR3
immunohistochemistry 5 days after the injection of LPS or control
buffer. To evaluate the effect of administering COMP-Ang1 protein
after LPS injection, we treated mice with COMP-Ang1 protein
(200 mg) just after LPS injection and evaluated the changes of
ICAM-1 expression in kidney 16 h after COMP-Ang1 protein
injection and the number of ERHR-3-positive macrophage in kidney
5 days after COMP-Ang1 protein injection.
Measurement of MAP, RBF, and glomerular filtration rate
Measurements of MAP were performed as described previously.36
COMP-Ang1 or vehicle was injected 3 days before LPS (8mg/kg,
i.p.) or control buffer injection (n¼ 8 in each group). Sixteen hours
after LPS or control buffer injection, the animals were anesthetized
with ketamine (100mg/kg) and xylazine (10mg/kg) and placed on a
thermostatically controlled surgical table. Cannulas (PE10) were
placed into the carotid artery to measure systemic MAP and in the
jugular vein for maintenance infusions. The MAP cannula was
connected to a pressure transducer (MLT1050/A Precision BP
transducer, ADInstruments, Castle Hill, Australia) and monitored
continuously using a PowerLab System (ADInstruments). Measure-
ments of RBF were performed as described previously.19 After the
mouse was placed on its right side, the left kidney was exposed
through a subcostal incision. The left renal arteries were isolated
for the determination of RBF using a blood flowmeter and probe
(0.5-mm, Type V; Transonic Systems, Ithaca, NY, USA). An
intravenous maintenance infusion of 2.25% bovine serum albumin
in normal saline was injected at 0.25 ml/g body weight/min during
the measurement. Determination of glomerular filtration rate was
performed with FITC-inulin as described previously.37 Sixteen hours
after LPS or control buffer injection (n¼ 10 in each group), an
intravenous maintenance infusion of 2.25% bovine serum albumin
in normal saline at a rate of 0.25ml/g body weight/min was started
1 h before experimentation; 0.75% FITC-inulin was added to the
infusion solution for the determination of glomerular filtration rate
as described previously.2 A bladder catheter (PE10) was used to collect
urine. Two 30-min collections of urine were obtained and weighed to
determine the volume. Blood for plasma inulin determination was
drawn between urine collections. FITC in plasma and urine samples
were measured using a SpectraMax Gemini fluorescence plate reader
(Molecular Devices, Sunnyvale, CA, USA).
Immunohistochemistry and immunofluorescence double
staining
Immunohistochemical analyses were performed as previously
described.20,38 The kidney blocks were sectioned at 5 mm and
stained with rabbit antihuman vWF (Chemicon International,
Temecula, CA, USA), ICAM-1 (BD Pharmingen, San Diego, CA,
USA) antibodies. For immunofluorescence staining, fresh-frozen
renal tissue was incubated with anti-PECAM-1 (Chemicon Inter-
national) or ER-HR3 (BMA Biomedical, Augst, Switzerland) and a
Cy3-labeled secondary antibody. Kidney tissues were incubated with
the TUNEL reaction mixture (Roche Applied Science, Indianapolis,
IN, USA) containing terminal deoxynucleotidyl transferase and
nucleotides including FITC-labeled dUTP. Ten digital images of
every other nonoverlapping  400 microscopic field across the renal
cortex and medulla were captured with a Zeiss Z1 microscope (Carl
Zeiss, Go¨ttingen, Germany). The area positive for vWF or ICAM-1
was evaluated from the unit area ( 400 magnification field) and
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expressed as a percentage per unit area using a digital image analysis
program (AnalySIS, Soft Imaging System, Mu¨nster, Germany).39
Immunoblotting
Immunoblotting was performed as previously described.40
Serum nitrate/nitrite levels
Blood samples were taken from mice 16 h after the administration of
LPS (8mg/kg) or control buffer (n¼ 4 in each group). Serum
nitrate/nitrite levels were determined by using a commercial kit
(Nitrate/Nitrite Colorimetric Assay Kit, Cayman Chemical Com-
pany, Ann Arbor, MI) according to the manufacturer’s instructions.
Absorbance was read at 540 nm using a THERMOmax microplate
reader (Molecular Devices).
Vascular permeability measurement using Evans blue dye
The microvascular leakage of Evans blue dye was assessed as
described previously.9 Thirty minutes before killing, the mice were
anesthetized with ketamine (100mg/kg) and xylazine (10mg/kg)
and injected i.v. with 2ml Evans blue dye (1% in 0.9% NaCl
solution) per kilogram body weight through the tail vein. At killing,
the mice were perfused with normal saline through the left ventricle
until all blood was eliminated. The kidneys were excised,
decapsulated, dried by centrifugation at 25 1C under vacuum, and
weighed to estimate the dry weight. The kidneys were homogenized
in 1ml of formamide, incubated at 55 1C for 18 h, and then
centrifuged at 16,000 g for 30min at 4 1C The amount of Evans blue
in the supernatant was determined by measuring absorbance
at 620 nm with a SmartSpec Plus spectrophotometer (BioRad,
Hercules, CA, USA) and correcting for the extraction volume.
Transmission electron microscopy
Electron microscopy was performed as previously described.41
Ultrathin sections cut on an ultramicrotome (ULTRACUTE, Leica
Microsystems, Wetzlar, Germany) were counterstained with uranyl
acetate and lead citrate and examined in electron microscope (JEM-
1200EXII, JEOL, Tokyo, Japan).
Measurement of renal cortical and medullary blood flow
Changes in the blood flow in the superficial renal cortex and
medulla were measured using a laser-Doppler flow probe (1.2-mm
diameter, Type N; Transonic Systems), as described previously.18
Evaluation of ROS/RNS generation ex vivo and in vivo
To evaluate ROS/RNS generation in the kidney, we used a confocal
laser scanning microscope. At 16 h after the injection of LPS, 3mg/
kg DHR (Invitrogen, Eugene, OR) was administered i.v. After
15min, mice were anesthetized and subsequently killed by cervical
dislocation. Frozen sections of kidney were prepared for confocal
laser scanning imaging of DHR obtained with an LSM 510 META
confocal laser scanning microscope (Carl Zeiss). We used the
intravital microscope as previously described.18 In brief, 16 h after
injection of LPS, DHR (0.3mg/kg) was administered i.v. 15min
before examination. Kidneys were exposed by retroperitoneal
incision and episcopically illuminated (excitation¼ 535 nm, emis-
sion¼ 590 nm) under a fluorescence intravital microscope. Real-
time imaging was recorded at 30 frames/s using a Cascade 650 CCD
camera (Roper Scientific, Tucson, AZ) and MetaMorph software
(Universal Imaging, Sunnyvale, CA, USA). Six randomly selected
regions (250 180mm2) were evaluated at each time point.
Statistical analysis
Data are expressed as means±s.d. Student’s t-test was used to
compare the means of normally distributed continuous variables.
Multiple comparisons were examined for significant differences
using analysis of variance, followed by individual comparisons with
the Tukey post hoc test. Statistical significance was set at Po0.05.
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